國藥控股(01099.HK):2021年度歸母淨利77.59億元,同比增長7.95%
格隆匯3月21日丨國藥控股(01099.HK)發佈公吿,2021年度,集團實現營業收入人民幣5210.51億元,同比增長14.16%,增速明顯高於行業平均水平,市場份額持續擴大。集團把握業務轉型機遇,積極消化藥品和醫療器械帶量採購不斷擴面實施所帶來的藥械價格下降的影響,全年實現淨利潤人民幣130.65億元,同比增長8.00%,歸母淨利潤達到人民幣77.59億元,同比增長7.95%。建議派發年度末期股息每股人民幣0.75元(含税)。
醫療器械和醫藥零售板塊切實按照公司的發展規劃,在報吿期內持續保持相對高速的發展態勢,公司整體的業務格局進一步多元優化。就2021年度,集團藥品分銷板塊收入佔比同比下降1.56個百分點至72.62%,而醫療器械和藥品零售板塊則分別同比上升1.1個百分點和0.26個百分點,達到20.14%和5.41%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.